These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 32790958

  • 21. Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone.
    Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN.
    J Clin Microbiol; 2018 Aug; 56(8):. PubMed ID: 29848564
    [Abstract] [Full Text] [Related]

  • 22. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S, Schito AM, Marchese A, Schito GC.
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [Abstract] [Full Text] [Related]

  • 23. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
    Guss J, Abuzeid WM, Doghramji L, Edelstein PH, Chiu AG.
    ORL J Otorhinolaryngol Relat Spec; 2009 Nov; 71(5):263-7. PubMed ID: 19797934
    [Abstract] [Full Text] [Related]

  • 24. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 25. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
    Ciofu O, Giwercman B, Pedersen SS, Høiby N.
    APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
    Al-Obaidi H, Kalgudi R, Zariwala MG.
    Eur J Pharm Biopharm; 2018 Jul; 128():27-35. PubMed ID: 29654885
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of susceptibility of cystic-fibrosis-related and non-cystic-fibrosis-related Pseudomonas aeruginosa to chlorine-based disinfecting solutions: implications for infection prevention and ward disinfection.
    Moore JE, Rendall JC.
    J Med Microbiol; 2014 Sep; 63(Pt 9):1214-1219. PubMed ID: 24925907
    [Abstract] [Full Text] [Related]

  • 32. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H, Horii T, Takeshita A, Hashimoto H, Maekawa M.
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [Abstract] [Full Text] [Related]

  • 33. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
    Sousa AM, Monteiro R, Pereira MO.
    Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
    [Abstract] [Full Text] [Related]

  • 34. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019).
    Shortridge D, Pfaller MA, Streit JM, Flamm RK.
    J Glob Antimicrob Resist; 2020 Dec; 23():278-283. PubMed ID: 33068780
    [Abstract] [Full Text] [Related]

  • 35. Genome features and antibiotic resistance of Pseudomonas aeruginosa strains isolated in patients with cystic fibrosis in the Russian Federation.
    Bocharova YA, Savinova TA, Lyamin AV, Kondratenko OV, Polikarpova SV, Zhilina SV, Fedorova NI, Semykin SY, Chaplin AV, Korostin DO, Mayansky NA, Chebotar IV.
    Klin Lab Diagn; 2021 Oct 18; 66(10):629-634. PubMed ID: 34665950
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acquired fluoroquinolone resistance genes in corneal isolates of Pseudomonas aeruginosa.
    Khan M, Summers S, Rice SA, Stapleton F, Willcox MDP, Subedi D.
    Infect Genet Evol; 2020 Nov 18; 85():104574. PubMed ID: 32992031
    [Abstract] [Full Text] [Related]

  • 40. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR, Gonda I, Dahms J, Cipolla D, Davis AM, Chalmers JD, Froehlich J.
    Clin Microbiol Infect; 2019 Dec 18; 25(12):1532-1538. PubMed ID: 31035017
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.